Voyager Therapeutics (NASDAQ:VYGR) Shares Gap Down to $9.91

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report)'s share price gapped down before the market opened on Wednesday . The stock had previously closed at $9.91, but opened at $9.63. Voyager Therapeutics shares last traded at $9.63, with a volume of 99,912 shares.

Analyst Ratings Changes

VYGR has been the subject of a number of analyst reports. Citigroup initiated coverage on shares of Voyager Therapeutics in a report on Thursday, March 7th. They set a "buy" rating and a $16.00 target price for the company. Wells Fargo & Company upgraded shares of Voyager Therapeutics from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $9.00 to $14.00 in a report on Tuesday, January 2nd. HC Wainwright initiated coverage on shares of Voyager Therapeutics in a report on Tuesday, March 19th. They set a "buy" rating and a $30.00 target price for the company. Guggenheim initiated coverage on shares of Voyager Therapeutics in a report on Tuesday, March 26th. They set a "buy" rating and a $22.00 target price for the company. Finally, StockNews.com upgraded shares of Voyager Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, March 9th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $19.33.

Voyager Therapeutics Price Performance

The stock's 50 day simple moving average is $8.55 and its two-hundred day simple moving average is $7.89. The firm has a market cap of $507.71 million, a P/E ratio of 3.03 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $1.84. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. The business had revenue of $90.06 million during the quarter, compared to the consensus estimate of $4.95 million. Equities research analysts anticipate that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current year.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Kestra Advisory Services LLC bought a new stake in shares of Voyager Therapeutics during the third quarter valued at approximately $980,000. Ritholtz Wealth Management bought a new stake in shares of Voyager Therapeutics during the 3rd quarter valued at $137,000. Alps Advisors Inc. bought a new stake in shares of Voyager Therapeutics during the 3rd quarter valued at $294,000. Aigen Investment Management LP bought a new stake in shares of Voyager Therapeutics during the 3rd quarter valued at $109,000. Finally, Barclays PLC raised its position in shares of Voyager Therapeutics by 188.8% during the 3rd quarter. Barclays PLC now owns 18,309 shares of the company's stock valued at $141,000 after purchasing an additional 11,970 shares during the period. Institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.